Explore all of our publications and interviews in academic journals and mainstream media using the filter and search functions.
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020
We can't tackle the pandemic without figuring out which Covid-19 vaccines work the best
There may be several Covid-19 vaccines by winter, but there will also need to be a study comparing the viruses to one another as part of rolling out widespread vaccination.
Instead of debating 'first-shot' vs 'set-aside' vaccine approaches, hospitals' study should compare them
Hospitals could start studies of their own employees to answer important questions, including whether the first-shot approach has downsides when compared to the set-aside strategy.
After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
Many promising ideas won't work as expected, and that's all the more reason for CMS to evaluate how medical care is delivered to its patients.
The Science on Coronavirus is Topsy-Turvy. That's Fine.
Urgency demands patience, because advancement is always a product of missteps.
The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
COVID-19 Reduced Average Life Expectancy of Americans by Five Days, Not One Year
The CDC made a mistake.
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
Fact Checking the NYT Fact Check on the Trump Proposal
The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.
Drug Pricing Lab
A $475,000 price tag for a new cancer drug: crazy or meh?
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
What steps are needed to make outcomes-based contracting a value-based approach?
Morning Consult 06/21/2017
The U.S. Government Should Buy Gilead for $156Bn to Save Money on Hep C
At $500 per pill, buying Gilead could lower hepatitis C drug costs per patient to one-third their current level, making it affordable to rapidly treat the 2.7 million Americans that have HCV.
Do High Drug Prices Drive Innovation, Or Hurt It?
In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.
Forbes: Debate 11/03/2014
Could High Drug Prices Be Bad for Innovation?
Industry leaders argue that high prices are necessary for innovation, but just how high do prices need to be?
Forbes: Cancer 10/23/2014
Unpronounceable Drugs, Incomprehensible Prices
Cancer drug prices continue to rise. Just how much can pharmaceutical companies charge?
Forbes: Cancer 08/13/2014
No Results Found